歌禮製藥-B(01672.HK)公布,其全資附屬甘萊的戰略合作夥伴Sagimet Biosciences (SGMT.US)用於治療經肝穿活檢證實纖維化2/3期MASH患者的ASC40 (地尼法司他),獲得美國食品藥監局(FDA)突破性療法認定。歌禮已從Sagimet獲得ASC40的大中華區獨家授權。
Clear
All
Quotes
News
Learn
Help
All
US
HK
CN
SG
AU
JP
All
News
Announcements
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
歌禮製藥(01672.HK)戰略夥伴Sagimet藥物「地尼法司他」獲美國突破性療法認定
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Like
1
Views 306
Write a comment
1
Statement
This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report